|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for RERG |
 Gene summary |
| Basic gene Info. | Gene symbol | RERG |
| Gene name | RAS-like, estrogen-regulated, growth inhibitor | |
| Synonyms | - | |
| Cytomap | UCSC genome browser: 12p12.3 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001190726.1, NM_032918.2, | |
| Description | ras-related and estrogen-regulated growth inhibitor | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 612664 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000134533 | ||
| HPRD : 15238 | ||
| Vega : OTTHUMG00000168745 | ||
| Protein | UniProt: Q96A58 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_RERG | |
| BioGPS: 85004 | ||
| Pathway | NCI Pathway Interaction Database: RERG | |
| KEGG: RERG | ||
| REACTOME: RERG | ||
| Pathway Commons: RERG | ||
| Context | iHOP: RERG | |
| ligand binding site mutation search in PubMed: RERG | ||
| UCL Cancer Institute: RERG | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0008285 | negative regulation of cell proliferation | 11533059 | GO:0009725 | response to hormone | 11533059 | GO:0030308 | negative regulation of cell growth | 11533059 |
| Top |
| Ligand binding site mutations for RERG |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | G16 | R14I | LUAD | 1 | N118 | G117A | LUSC | 1 | L122 | L122V | STAD | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for RERG |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | L122 | L122V | -1.1477328 | G16 | R14I | -0.78264536 | N118 | G117A | -0.66019496 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for RERG from PDB |
| Top |
| Differential gene expression and gene-gene network for RERG |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for RERG |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for RERG |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of RERG go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | GDP | GUANOSINE-5'-DIPHOSPHATE | 2atv | A | G16 N118 L122 |
| Top |
| Conservation information for LBS of RERG |
| Multiple alignments for Q96A58 in multiple species |
| LBS | AA sequence | # species | Species | A149 | FYECSACTGEG | 3 | Homo sapiens, Bos taurus, Mus musculus | A21 | GVGKSALVVRF | 2 | Homo sapiens, Bos taurus | A21 | GVGKSAIVVRF | 1 | Mus musculus | C150 | YECSACTGEGN | 3 | Homo sapiens, Bos taurus, Mus musculus | D121 | VGNKADLDHSR | 3 | Homo sapiens, Bos taurus, Mus musculus | E34 | KRFIWEYDPTL | 3 | Homo sapiens, Bos taurus, Mus musculus | F31 | FLTKRFIWEYD | 3 | Homo sapiens, Bos taurus, Mus musculus | G16 | IFGRAGVGKSA | 3 | Homo sapiens, Bos taurus, Mus musculus | G18 | GRAGVGKSALV | 2 | Homo sapiens, Bos taurus | G18 | GRAGVGKSAIV | 1 | Mus musculus | K119 | ILVGNKADLDH | 3 | Homo sapiens, Bos taurus, Mus musculus | K19 | RAGVGKSALVV | 2 | Homo sapiens, Bos taurus | K19 | RAGVGKSAIVV | 1 | Mus musculus | L122 | GNKADLDHSRQ | 3 | Homo sapiens, Bos taurus, Mus musculus | N118 | LILVGNKADLD | 3 | Homo sapiens, Bos taurus, Mus musculus | S148 | AFYECSACTGE | 3 | Homo sapiens, Bos taurus, Mus musculus | S20 | AGVGKSALVVR | 2 | Homo sapiens, Bos taurus | S20 | AGVGKSAIVVR | 1 | Mus musculus | V17 | FGRAGVGKSAL | 2 | Homo sapiens, Bos taurus | V17 | FGRAGVGKSAI | 1 | Mus musculus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |